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ABSTRACT

Fulkerson, Christopher M. D.V.M, M.S., Purdue University, August 2014.
Pharmacokinetics and Toxicity of the Novel Oral Demethylating Agent Zebularine in
Tumor Bearing Dogs. Major Professor: Deborah Knapp.
The aim of this thesis is to investigate the pharmacokinetics and toxicity of the novel oral
demethylating agent zebularine (zeb) in laboratory dogs and tumor bearing dogs. This
thesis focuses on the application of this therapeutic strategy in dogs with naturally
occurring invasive transitional cell carcinoma (InvTCC), which serve as a relevant model
of the human disease.

DNA hypermethylation in the promoter region is a common epigenetic change in cancer
that silences tumor suppressor genes. Zeb is an oral cytidine analog that acts as a
demethylating agent. Zeb has been investigated extensively in vitro as well as in mice,
rodents and rhesus monkeys. Prior to the investigation described in this thesis, zeb had
not been investigated in the dog. The authors set out to investigate zeb in dogs with
naturally occurring InvTCC with an eventual goal of applying this treatment strategy to
humans with this devastating cancer.

The first part of this thesis reviews the importance of DNA methylation in cancer
development, the development and application of zeb as a novel oral demethylating agent

xi
and the application of demethylating agents in InvTCC in the dog. The second part of
this thesis presents initial pharmacokinetics and toxicity data following high dose oral zeb
in laboratory dogs (n=3) and tumor bearing dogs (n=3). Daily high dose oral zeb at 4 mg
kg-1 resulted in remarkable, but reversible, hematologic toxicity in the form of
neutropenia in laboratory dogs. Dose adjustment revealed that a dose intensity of 4 mg
kg-1 once every 21 days was well tolerated in tumor bearing dogs. The third part of this
thesis presents the results to date of a phase I dose escalation trial of oral zeb in 26 dogs
with InvTCC. At daily doses up to 0.5 mg kg-1, zeb was well tolerated. At higher doses,
dose-limiting toxicity (DLT) was detected. In a population in which 73% of dogs had
failed previous treatment, overall disease control rate of 73.3% was detected, and median
progression free survival time was 86 days (95% CI, 47.5-124.5). Of particular interest is
that one dog has experienced disease stabilization for more than 511 days.

Remarkable, but reversible, neutropenia was detected in laboratory dogs treated with high
dose daily zeb. Low dose daily zeb at doses up to 0.5 mg kg-1 was well tolerated in dogs
with InvTCC. Initial results indicate promising disease control rates and progression free
survival in a population of dogs that was heavily pretreated. These results warrant further
investigation as a treatment strategy in dogs with InvTCC with potential applications to
the human disease. Further investigation is required to determine if the optimal effects of
zeb may be in combination with cytotoxic chemotherapy drugs and to document that
tumor responses are due to DNA demethylation and reactivation of silenced genes.
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CHAPTER 1. INTRODUCTION

1.1

Introduction

Epigenetic changes are heritable changes that alter gene expression without
changing the DNA sequence.1,2 DNA methylation is one of the most studied epigenetic
changes in mammals. DNA methylation may become dysregulated due to altered DNA
methyltransferase (DNMT) activity and other changes associated with chronic
inflammation and exposure to carcinogens.1 DNA methylation in mammals occurs on
cytosine residues in the 5’ position to guanine residues in a cytosine guanine dinucleotide
(CpG).2,3
CpGs are unevenly distributed throughout the genome and are concentrated
within short repeats called CpG islands.3 These CpG islands are concentrated within the
promoter regions of half or more of all mammalian genes.2,3 In normal cells, promoter
region CpG islands are usually unmethylated, whereas in cancer cells, these regions are
often hypermethylated. Hypermethylation of promoter region CpG islands results in
transcriptional silencing.3 Hypermethylation of DNA within a gene promoter region
prevents binding of the transcriptional apparatus by physically blocking its interaction
with DNA.1 Methylation attracts methyl-CpG binding proteins which attract histone and
chromatin remodeling complexes that alter the conformation of chromatin from the
transcriptionally active euchromatin to transcriptionally silent heterochromatin.1,2

2
DNA methylation is mediated by DNMTs.3,4 DNMTs are responsible for
establishing and maintaining the patterns of methylation throughout DNA synthesis.4
DNMTs transfer methyl groups from S-adenosyl-l-methionine to CpGs as DNA is
replicated during S-phase.1,4 When the CpG on one daughter strand pairs with a CpG
on the complementary strand of DNA, the resultant pair can be unmethylated,
partially methylated (hemi-methylated) or completely methylated. DNMT1
preferentially binds to partially methylated CpG pairs, restoring a completely
methylated state.4 DNMT1 is largely responsible for maintenance methylation, while
DNMT3a and DNMT3b are responsible for de novo methylation.2,3,5 De novo
methylation is associated with aging and inflammation, and likely occurs early in
tumor development.3 Expression of DNMT3a and 3b is high during embryogenesis,
and low in adult cells.2 Expression of DNMT is essential to development as indicated
by the fact that mice deficient in either DNMT1 or DNMT3b are embryonic lethal,
and mice deficient in DNMT3a die before they are 4 weeks old.2
Tumor suppressor gene function can be lost due to hypermethylation of gene
promoter regions, mutations and DNA loss through deletions.4 DNA
hypermethylation is frequently the “second hit” in familial cancers, leading to gene
inactivation.3 Transcriptional silencing by promoter hypermethylation has been
demonstrated in important genes involved in apoptosis, DNA repair, cell cycle
regulation, metastasis/invasion and hormone receptors.2,3 The list of human genes
that have been documented as silenced through DNA methylation include ATM
(ataxia telangiectasia mutated), APC (adenomatosis polyposis coli), BRCA2 (breast
cancer 2, early onset), CDH1 (E-cadherin), CDKN2A (cyclin-dependent kinase
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inhibitor 2A), GSTP1 (glutathione S-transferase pi), P14ARF, P15, P16INK4A PTEN
(phosphatase and tensin homologue), RASSF1A (Ras association domain containing
protein 1a) RB1 (retinoblastoma 1) and TIMP3 (tissue inhibitor of metalloproteinase
3).3
DNA hypermethylation can also contribute to genomic instability and tumor
progression by promoting genetic mutation.2,3 Silencing of MLH1 (mutL homologue
1), a mismatch repair gene, is often seen in colon and endometrial cancers with
microsatellite instability. Hypermethylation of MLH1 has also been demonstrated
within adjacent normal colonic epithelium of people with colon cancer, and
hyperplastic tissue in people with endometrial cancer.3 Hypermethylation of MGMT
(O6-methylguanine-DNA methyltransferase), a gene that repairs carcinogen induced
DNA adducts, has been detected in a variety of malignancies, and may facilitate
mutations in p53 and K-RAS.1,3
Unlike genetic mutations, DNA methylation is a potentially reversible
heritable change.2,3,6 There are currently two Food and Drug Administration
approved injectable demethylating agents in use for the treatment of human
myelodysplastic syndrome, 5-azacytidine (Vidaza®, Celgene Corp., Summit, NJ,
USA; 5-Aza-CR) and decitabine (Dacogen®, SuperGen, Inc., Dublin, CA, USA; 5Aza-CDR).1 5-Aza-CR has been investigated in dogs with invasive transitional cell
carcinoma (InvTCC), resulting in 22% partial remission and 50% stable disease for
more than 8 weeks. Since demethylating agents function by interfering with the
activity of DNMTs during DNA replication, continuous exposure in the form of daily
oral administration may be the most effective delivery strategy.1,7

4
Zebularine (1-β-D-Ribofuranosyl-2(1H)-pyrimidinone; zeb) is another
demethylating agent that is very similar in structure to 5-Aza-CR and 5-Aza-CDR,
but it is stable under a wide range of conditions and can be administered orally.6,8
The purpose of this work is to describe initial results of investigation of zeb in the dog
including initial pharmacokinetics and toxicity in laboratory and tumor bearing dogs,
and a phase I dose escalation trial in dogs with InvTCC.
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CHAPTER 2. LITERATURE REVIEW

2.1

Introduction

This chapter will begin with a review of the available literature on zebularine’s (zeb)
mechanisms of action as a cytidine deaminase (CDA) inhibitor, DNA methyltransferase
(DNMT) inhibitor and radiosensitizer. Then, this chapter reviews zeb’s activity in vivo
and in vitro and its pharmacokinetics in rodents and monkeys. Finally, this chapter
provides an introduction to human and canine invasive transitional cell carcinoma
(InvTCC), and the basis for the application of demethylating therapy in this disease.

2.2

Zebularine

Zeb is the 4-desamino analog of cytidine.1-4 Zeb was first synthesized in 1961.3
Zeb was originally identified as a bacteriostatic drug, then determined to be a potent
CDA inhibitor and more recently determined to be a DNMT inhibitor.3-5 In addition, zeb
acts as a radiosensitizer.6,7 Zeb’s physical characteristics make it ideal for oral
administration. Zeb has a half-life of 44 hours at 37°C in phosphate buffered saline at pH
1.0, and 508 hours at pH 7.0.2 The triazine ring of 5-azacytidine (Vidaza®, Celgene
Corp., Summit, NJ, USA; 5-Aza-CR) and decitabine (Dacogen®, SuperGen, Inc., Dublin,
CA, USA; 5-Aza-CDR) rapidly decompose even at neutral pH.3 Unlike 5-Aza-CR and 5Aza-CDR, which rapidly decompose even at neutral pH, zeb is stable over a broad pH

7
range and is not subject to rapid inactivation by CDA.3,4 The stability of zeb over a
broad pH range allows for oral administration, unlike 5-Aza-CR and 5-Aza-CDR.2
While zeb has not been demonstrated to be as potent as 5-Aza-CR or 5-AZa-CDR in
vitro or in vivo, its stability and reported lack of toxicity allows for chronic or
continuous administration.3 Once incorporated into DNA, zeb is as potent as 5-AzaCR.5

2.3

Zebularine inhibits the activity of cytidine deaminase

After zeb’s initial synthesis, it was determined to be an inhibitor of CDA.3,4,8,9
CDA is normally involved in the pyrimidine salvage pathway and converts cytidine
and deoxyctidine to uridine and deoxyuridine. CDA is important in the metabolic
disposition of nucleoside analogs including cytosine arabinoside and 5-Aza-CDR.
CDA rapidly deaminates cytosine arabinoside and 5-Aza-CDR, resulting in their
inactivation.4,9
Unlike other nucleoside analogs, zeb is not subject to deamination by CDA,
but rather inhibits the enzyme’s activity. Zeb can enhance the activity of 5-Aza-CDR
and cytosine arabinoside by inhibiting their CDA mediated degradation.4,8, The
combination of zeb and either cytosine arabinoside or 5-Aza-CDR resulted in
improved survival in tumor bearing mice with L1210 or P388 leukemia.3
Upregulation of CDA occurs in relapsed leukemias, and can be an important
mechanism of resistance to 5-Aza-CDR and cytosine arabinoside.8
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2.4

Zebularine is incorporated into DNA and inhibits DNMTs

Cytidine analogs are incorporated into DNA in place of cytosine residues.1
Once incorporated into DNA, zeb forms a complex with DNMTs, thus inhibiting
methylation. The mechanism of action of zeb’s demethylating activity is essentially
identical to 5-Aza-CR and 5-Aza-CDR.1,4,10 The target for DNMTs is normally the
second cytosine base in a GCGC sequence. Normally, a cytosine base undergoes
methylation at the 5’ position when it rotates out of the DNA helix through a process
called base flipping.1,3 When zeb rotates out of the DNA helix, a covalent bond
forms between the zeb incorporated DNA and the DNMT, resulting in a stable
nucleoprotein complex.1
As these zeb-DNA-DNMT complexes form throughout the genome, DNMTs
are sequestered and depleted, resulting in decreased DNMT activity.11 Following zeb
treatment, DNMT1’s activity is decreased first. In vitro, the activity of DNMT1 is
frequently completely inhibited. The activity of DNMT3b and then DNMT3a are
also decreased, but not as robustly. A lack of change in DNMT RNA transcripts
following zeb treatment supports that zeb’s mechanism of action is sequestration of
DNMT in stable nucleoprotein complexes.3
Activation of zeb is complicated and inefficient. Zeb must undergo
phosphorylation and conversion into its deoxynucelotide before it can be incorporated
into DNA.3,4 Zeb is converted to 2’-deoxyzebularine-5’monophosphate (dZMP), 2’deoxyzebularine-5’diphosphate (dZDP), 2’-deoxyzebularine-5’triphosphate (dZTP),
2’-deoxyzebularine-5’diphosphocholine (ZDP-chol) and 2’-deoxyzebularine5’diphosphoethanolamine. The metabolites dZTP and ZDP-chol are the most
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common, but only the triphosphate dZTP can be incorporated into DNA. The rate
limiting step in the zeb’s activation and incorporation into DNA is the conversion of
zebularine-5’diphosphate to dZDP via ribonucleotidediphosphate reductase. Up to
sevenfold more zeb is incorporated into RNA than DNA.3

2.5

Zebularine is preferentially incorporated into tumor cells compared to normal
fibroblasts
One concern with the use of demethylating agents is the induction of global

genome hypomethylation, which has been associated with cancer and genomic
instability.1,10 While demethylation of the hypermethylated promoter region of a
tumor suppressor gene would be beneficial in cancer therapy, removing repressive
methylation from the promoter region of a proto-oncogene within a tumor could have
deleterious results.1 Interestingly, zeb appears to be preferentially incorporated into
the DNA of human tumor cells compared to normal human fibroblasts in vitro.10
Zeb’s activity was investigated in seven human cancer cell lines (T24, HCT15,
CFPAC-1, SW-48, HT-29, PC3 & CALU-1) and four normal human fibroblast cell
lines (LD98, T-1, LD419 & CCDD-1070Sk). Following continuous treatment with
1,000 µM zeb, the doubling time increased in all seven cancer cell lines. The cancer
cell lines appeared to be more susceptible to the affects of zeb than normal fibroblasts.
Doubling times increased from 33 to 68% in the tumor cell lines and by 12 to 21% in
fibroblast cell lines. A two- to sevenfold increase in p21, which encodes a protein
that binds to proliferating cell nuclear antigen and halts DNA replication, was
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detected in the cancer cell lines following zeb treatment. No significant changes in
p21 were detected in fibroblasts.10
Promoter methylation resulting in transcriptional silencing of p16 was known
to be present in all seven cancer cell lines, while normal p16 was present in the
fibroblast cell lines. Following 1,000 µM zeb treatment, p16 mRNA levels remained
unchanged in human fibroblasts, but p16 was induced in five cancer cell lines (T24,
HCT15, CFPAC-1, SW48 and HT-29). With continued zeb treatment, p16
expression was induced in a sixth cancer cell line (CALU-1). The growth inhibitory
affects of zeb appear to be due to a combination of upregulation of p21 in all seven
cell lines and induction of p16 in five of the cell lines.10
Levels of DNMT1 were evaluated and determined in all seven cancer cell
lines and human fibroblasts. DNMT1 activity was decreased in the normal
fibroblasts and two cancer cell lines (PC3 and CALU-1), but residual activity was still
present. Levels of DNMT1 were almost completely depleted in T24, HCT-15,
CFPAC-1, SW48 and HT-29 cell lines. DNMT1 mRNA levels were unchanged,
supporting that depletion occurred due to sequestration of DNMT within zeb-DNADNMT complexes. Zeb’s growth inhibitory effects were not as great in the cancer
cell lines that did not have complete depletion of DNMT1 (PC3 and CALU-1) and
normal human fibroblasts.10 Overall, cancer cells were more susceptible to zeb
induced growth inhibition, and DNMT1 was almost completely inhibited in five of
the cell lines.
Differences in zeb’s activity in cancer cells compared to normal cells may be
due to differences in metabolic pathways. Uridine/cytidine kinase is responsible for
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zeb phosphorylation, which is necessary for zeb activation and incorporation into
DNA. The activity of uridine/cytidine kinase was three to 40 times greater in cancer
cell lines compared to human fibroblasts. The fact that CALU-1, a cancer cell line
that was resistant to zeb, had low uridine/cytidine kinase activity supports that this
pathway is important in responsiveness to zeb. The uridine/cytidine kinase pathway
likely regulates how much zeb is eventually incorporated into DNA and this enzyme
is more expressed in many cancer cell lines compared to normal fibroblasts.10 The
potential for sparing normal tissues is a significant advantage, and may allow for
accumulation of zeb within tumor tissues while avoiding toxicity to normal cells.

2.6

Zebularine is a radiosensitizer

Dote et al. investigated zeb’s influence on DNA methylation and
radiosensitivity in human cell lines from histologies that are normally treated with
radiation therapy including MiaPaCa (pancreatic carcinoma), U251 (glioblastoma)
and DU145 (prostate carcinoma). Methylation-specific polymerase chain reaction
was used to detect methylation of RASSF1A, HIC-1 and 14-3-3σ, three genes that are
frequently methylated in human cancers. All three genes were methylated in
MiaPaCa and U251 cell lines. RASSF1A was methylated, HIC-1 was partially
methylated and 14-3-3σ was unmethylated in the DU145 cell line.6
Following treatment with zeb for 48 hours at 200 µM (MiaPaCa) and 300 µM
(U251 and DU145), increased unmethylated RASSF1A and HIC-1 were detected in all
three cell lines, and unmethylated 14-3-3σ was detected in MiaPaCa and U251 tumor
cells. Reverse transcription-PCR analysis revealed increased expression of RASSF1A
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and HIC-1 in all three cell lines, and increased expression of 14-3-3σ in MiaPaCa and
U251 cell lines. Unmethylated RASSF1A was detectable within 24 hours of zeb
treatment. Treatment of all three cell lines with zeb for 24 hours prior to treatment
with up to 8 gray (Gy) increased radiosensitivity. The maximum increase in
radiosensitivity was observed following zeb treatment for 48 hours prior to
irradiation.6
In vivo effects of the combination of zeb and radiation were investigated in
male NCr nu/nu mice implanted with U251 xenografts. To determine the
demethylating activity of zeb in U251 xenografts, zeb was administered at 350 mg
kg-1 by intraperitoneal injection for 5 days and tumor samples were evaluated by PCR
for RASSF1A, HIC-1 and 14-3-3σ. Expression of all three genes was maximized
following three days of zeb treatment compared to controls, with no increase detected
with additional days of treatment. Mice were randomized to no treatment, zeb alone,
radiation alone (4 Gy) or zeb and radiation, and then tumor growth was evaluated.
The time for tumors to reach a size of 1,400 mm3 in mice treated with the
combination of zeb and radiation was significantly increased compared to all other
treatment groups.6
Kim et al. investigated six DNMT inhibitors including 5-Aza-CR, 5-Aza-CDR,
zeb, hydralazine, epigallocatechin gallate (EGCG) and psammaplin A on
radiosensitivity in vitro in A549 (human lung cancer with a wild type p53) and
U373MG (human glioblastoma with an inactive p53 mutant) cell lines. A zeb
concentration of 800 µM was used because this was the in vitro IC50 for these cell
lines. Treatment with 5-Aza-CDR, zeb and psammaplin A before irradiation with up
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to 8 Gy resulted in significantly enhanced radiation cell killing in both cell lines.
Western blot revealed depletion of DNMT1 and DNMT3a in both cell lines following
treatment with 5-Aza-CDR, zeb and psammaplin A, but no change in DNMT3b.7

γH2AX expression, which is associated with radiation induced double strand
DNA breaks, is increased following irradiation with zeb pretreatment.6,7 In MiaPaCa,
U251 and DU145 cell lines pretreated with zeb followed by irradiation, γH2AX
expression was not increased one hour following irradiation, but was significantly
greater at 24 hours when compared to controls treated with irradiation alone.6
Similarly, γH2AX expression in A549 and U373MG cell lines was no different 1 hour
after irradiation with 5-Aza-CDR, zeb and psammaplin A pretreatment, but increased
significantly over time compared to irradiation alone.7 Increased γH2AX expression
suggests persistent, unrepaired double strand breaks and that zeb enhanced
radiosensitivity may be due to inhibition of DNA repair.6,7
Meador et al. determined that the DNA-dependent protein kinase (DNA-PK)
deficient human glioblastoma cell line MO59J was more sensitive to zeb treatment up
to 300 µM compared to MO59K, a DNA-PK proficient human glioblastoma cell line.
DNA-PK is a member of the phosphatidylinositol-3 kinase super family and normally
functions to remove DNA damage such as double strand breaks or adducts. DNA-PK
deficient cells are inherently sensitive to radiation due to an inability to repair DNA
damage. Prolonged G2/M arrest is usually detected in DNA-PK deficient cells, but
this arrest was not detected following zeb treatment in the MO59J cell line. Following
treatment with zeb, the MO59J cell line demonstrated increased genomic instability
indicated by increased numbers of centrosomes per cell, polyploid cells and
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micronuclei formation indicating chromosome breakage and mis-segregation.
DNMT1 is normally involved in the repair of UV-laser induced double strand breaks,
and its depletion by zeb may result in impaired DNA repair. Defects in DNA repair
and cell cycle checkpoint mechanisms resulted in enhanced zeb cytotoxicity as a
single agent in the DNA-PK deficient MO59J cell line.12
Demethylation and reactivation of specific genes and increased
radiosensitivity has been demonstrated following zeb pretreatment in vitro and in
vivo.6,7 Results of these studies suggest that the combination of radiation therapy and
zeb pretreatment may be clinically useful. Evidence suggests that radiosensitivity
may be enhanced following zeb pretreatment due to inhibition of DNA repair,
potentially due to depletion of DNMT1 or enhancement of inherently dysregulated
cellular pathways within a tumor such as DNA-PK.6,7,12 Zeb’s increased uptake in
tumor cells compared to normal cells10 would support its utility as a radiosensitizer,
as it would be expected to accumulate in tumor tissue and not nearby normal tissues.
While the use of high concentrations of zeb have been reported prior to irradiation,
the minimum zeb concentration required to achieve enhanced radiosensitivity remains
unknown. Future efforts should be aimed not only at determining the optimal
delivery schedule, but the minimum zeb dose required to achieve the desired
radiosensitization.

2.7

Zebularine inhibits tumor growth and reactivates silenced genes

Zeb administered by intravenous or intraperitoneal injection, oral gavage or in
drinking water is reported to be well tolerated in vivo in genetically tumor-prone
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mice13, transgenic mice14, mice harboring tumor xenografts15-17 and mice with
radiation-induced tumors.18 Demethylating activity that correlates with tumor
responses including stable disease, delayed or decreased tumor development and
decreases in tumor volume compared to untreated controls have been reported.13-18
The reported dose of zeb administered to mice has varied between studies.
Neuriter et al. reported the use of a relatively high dose of 1,000 mg kg-1 by
intraperitoneal injection in mice with pancreatic tumor xenografts. Male NMRI mice
with human Panc-89 cells implanted into the flank were allowed to develop seven
millimeter tumors. Mice were then treated daily for seven days with either zeb or
saline by intraperitoneal injection. Tumors in zeb treated mice remained stable in size
over the seven day period, while there was a statistically significant increase in size of
tumors in saline treated controls. Untreated tumors increased in size by 33% over the
same period of time.15 While shrinking tumors is often considered the goal of
chemotherapy, arresting tumor growth may be sufficient to improve patient outcomes
in many tumor types.
Herranz et al. used a lower zeb dose in a long-term injectable treatment
protocol in C57BL/6J mice treated with gamma irradiation to induce T-cell thymic
lymphoma. Mice were treated with 400 mg kg-1 by intraperitoneal injection for 78
days or phosphate buffered saline. Control mice treated with phosphate buffered
saline died, as expected, of thymic lymphoma within six months of irradiation. Mice
treated with zeb had significantly improved survival compared to controls. Of 30
mice treated with zeb, 40% (n=12) were still alive 12 months after irradiation.
Decreased levels of DNMT1 and a 30% decrease in 5-methylcytosine were detected
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in the thymus of mice treated with zeb that survived for 12 months when compared to
thymic lymphomas that developed in controls. Demethylation of hypermethylated
promoters of p16Ink4a, MGMT, MLT-1, and E-cadherin was detected along with
expression of the protein products. No remarkable toxicity was detected and
thorough necropsies were performed.18 This is one of the longest reported zeb
treatment protocols in mice, and demonstrated that continuous zeb administration was
feasible and safe in mice.
Zeb was the first demethylating agent to demonstrate effective demethylation
and antitumor effects following oral administration. Cheng et al. treated mice with
bladder cancer xenografts with up to 1,000 mg kg-1 zeb by oral gavage or
intraperitoneal injection. Male BALB/c nu/nu mice had EJ6 bladder cancer cells
implanted into the flank, and were then treated with zeb for 18 days. Minimal weight
loss and no deaths were reported in treated mice. Tumor growth was significantly
inhibited following treatment with 1,000 mg kg-1 orally or by intraperitoneal injection.
The p16 promoter, which is normally methylated in EJ6 cells, was significantly
hypomethylated in tumors from mice treated with 500 or 1000 mg kg-1 orally or
intraperitoneally compared to untreated controls. The detection of tumor growth
inhibition and demethylating effects in vivo following oral administration confirmed
zeb’s stability and demonstrated its clinical potential.17
Zeb also appeared to be effective following oral administration at even lower
doses in mice. Female BALB/c nu/nu mice had BGC823 gastric cancer cells
implanted into the flank, and were then treated with up to 100 mg kg-1 by oral gavage
once every four days for 20 days. No morbidity or mortality was reported, and a
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significantly decreased tumor weight was detected at day 20 for doses of 10 mg kg-1,
50 mg kg-1 or 100 mg kg-1 compared to controls. Expression of p16 and BAX
increased and expression of BCL-2 decreased as zeb concentration increased.16
Alternatives to oral gavage including spiking drinking water with zeb have
also been reported. Treatment with zeb in drinking water was well tolerated in a
majority of Min mice and resulted in tumor reduction in female mice. These mice
harbor a defect in the APC gene that leads to development of benign intestinal
adenomas. Most mice treated with 0.2 mg mL-1 zeb in drinking water from birth for
120 days appeared to be normal and healthy, but 14% died between weeks five and
seven of treatment. Importantly, this mortality may be a result of an exaggerated
sensitivity to zeb in Min mice as a dose of 1 mg mL-1 resulted in 100% death and a
dose of 0.1 mL-1 resulted in 100% survival. In female Min mice, average polyp
number decreased from 58 to one. In male Min mice, there was no change in the
average polyp number. There were no reported differences in toxicity based on sex.13
This was the first report of a sex difference in mice treated with zebularine. This
difference may be explained by differential activity of aldehyde oxidase in male mice
compared to females.19 The role of aldehyde oxidase in zeb metabolism is further
discussed later in this chapter.
While Min mice died following a dose of 1 mg mL-1 zeb in drinking water,
transgenic female FVB/N-Tg(MMTV-PyMT)634Mul mice tolerated treatment with 5
mg mL-1 zeb in drinking water. These mice spontaneously develop mammary tumors
by 60 days of age. Zeb treatment began at 46 days of age and resulted in a
statistically significant 10 day delay in the onset of tumor development compared to
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untreated controls. Mice were treated for 48 days and then sacrificed to determine
total tumor burden, which was significantly decreased in treated mice compared to
controls. Treatment morbidity and mortality were not reported.14
Overall, zeb is reportedly well tolerated over a wide range of doses and routes
of administration in mice. Significant tumor responses and changes in DNA
methylation have been detected in vivo, providing strong evidence that zeb may be
clinically useful.

2.8

Zebularine pharmacokinetics in mice, rats and rhesus monkeys

Initial investigation into zeb’s pharmacokinetics was performed in mice, rats
and rhesus monkeys. Animal subjects consisted of five to six week old male CD2F1
mice, seven to eight week old male Fischer 344 rats and six to nine year old male and
female rhesus monkeys (Macaca mulatta). Mice received a zeb dose of either 100
mg kg-1 intravenously or 1,000 mg kg-1 orally. Rats received a zeb dose of either 50
mg kg-1 intravenously, 250 mg kg-1 orally or 500 mg kg-1 orally. One male and one
female rhesus monkey each received a zeb dose of either 500 or 1,000 mg kg-1
intravenously on day one and then the same dose orally 16 days later. Serial blood
samples were collected over the next 24 to 48 hours and processed to plasma.20
Peak zeb plasma concentrations following intravenous injection in mice were
between 354 and 702-µg mL-1 (1,550 to 3,070 µM), half-life was 40 minutes with an
AUC of 7,323 µg mL-1. Peak zeb plasma concentrations following oral
administration in mice were between 28 and 35 µg mL-1 (120 to 150 µM) at 90
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minutes. Plasma zeb remained above the lower limit of quantification (0.03 µg mL-1)
for 960 minutes. AUC was 4,935 µg mL-1 and oral bioavailability was 6.7%.20
Peak zeb plasma concentrations following intravenous injection in rats were
between 165 and 238-µg mL-1 (723 to 1,040 µM), half-life was 363 minutes with an
AUC of 12,526 µg mL-1. Peak zeb plasma concentrations following oral
administration of 250 mg kg-1 in rats were between 10 and 11 µg mL-1 (44 to 48 µM)
at 120 minutes. AUC was 1,969 µg mL-1 and oral bioavailability was 3.1%. Peak zeb
plasma concentrations following oral administration of 500 mg kg-1 in rats were
between 31 and 32 µg mL-1 (135 to 140 µM) at 120 minutes. The AUC was 7,612 µg
mL-1 and oral bioavailability was 6.1%.20
Intravenous administration of 500 mg kg-1 resulted in a peak zeb plasma
concentration of 1,094 µg mL-1 (4,794 µM) in a male rhesus monkey and 537 µg mL-1
(2,350 µM) in a female rhesus monkey at five minutes. Plasma zeb concentration
decreased to below the level of quantification after 480 minutes in the male monkey
and 240 minutes in the female monkey. Estimated half-life was 70 and 76 minutes,
AUC were 88,020 and 46,080 µg mL-1. Oral administration of 500 mg kg-1 resulted
in a peak zeb plasma concentration of 0.37 and 0.18 µg mL-1 (1.6 and 0.79 µM) at 60
and 30 minutes. AUC was 84 and 12 µg mL-1. Oral bioavailibilities following an
oral dose of 500 mg kg-1 were 0.1% and 0.026%.20
Intravenous administration of 1000 mg kg-1 resulted in a peak zeb plasma
concentration of 1,656 µg mL-1 in a male rhesus monkey and 2,853 µg mL-1 in a
female rhesus monkey at five minutes. Plasma zeb concentration was above the level
of quantification for 24 hours following administration. Estimated half-life was 150
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and 147 minutes, and AUC was 104,520 and 281,220 µg mL-1. Oral administration
of 1,000 mg kg-1 resulted in peak zeb plasma concentrations of 0.5 and 0.92 µg mL-1
at 30 minutes and 8 hours. AUC was 42 and 1,128 µg mL-1. Oral bioavailabilities
following an oral dose of 1,000 mg kg-1 were 0.04% and 0.4%.20
Based on the pharmacokinetic parameters determined in mice, rats and rhesus
monkeys, frequent administration of zeb was recommended in order to achieve
desired plasma levels. The relatively low bioavailability, particularly in rhesus
monkeys, was surprising and led to the suggestion that continuous intravenous
administration or frequent oral dosing would be required. The reason for the low
bioavailability, particularly in rhesus monkeys, was unknown, but suggested causes
included first pass metabolism by aldehyde oxidase or saturation of an absorption
pathway in the intestines.20
Interestingly, when male cynomolgus monkeys (Macaca fascicularis) were
treated with continuous zeb infusions for five days out of seven designed to achieve
plasma concentrations of 10 or 15 µM, toxicity was detected. Toxicity included
elevated white blood cell counts, reticulocyte counts, alanine aminotransferase (ALT),
lactate dehydrogenase (LDH) and creatine kinase (CK). Treatments designed to yield
plasma concentrations of 25 to 50 µM or bolus intravenous injections of 500, 750 or
1000 mg kg-1 proved lethal. Rapid rises in zeb plasma concentrations prior to death
were suggestive of impaired zeb clearance, possibly due to liver or kidney injury.
Bolus doses ≤ 250 mg kg-1 resulted in elevated renal and liver values but no deaths.21
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2.9

Aldehyde oxidase and zebularine metabolism

Zeb is ultimately metabolized to uridine, uracil and dihydrouracil, all of which
are normally present in the body. In a study of zeb metabolism in male CD2F1 mice,
approximately 38% of zeb was oxidized to uridine by aldehyde oxidase (AO).22 AO
activity was evaluated in hepatic cytosol from mice, rats, humans, a male cynomolgus
monkey and a male Beagle dog. Among the species in which activity was detectable,
the activity was highest in male mice and lowest in female mice. Activity was not
detectable in hepatic cytosol from a male Beagle dog. A 50-fold difference was
detected between male and female mice, but a similar magnitude of difference was
not detected between sexes in rats or humans.19 there is often greater AO homology
between mice and humans than monkeys and humans.4
Supraphysiologic concentrations of uridine have been reported to cause
hyperthermia and hypothermia in mice. In humans, prolonged infusions of uridine
have been reported to cause hyperthermia and shivering has been reported during
shorter high dose infusions. The shivering reported in humans does not appear to be
due to changes in body temperature, and may be due to interference in the
metabolism of neurotransmitters like dopamine and neuropeptide. Based on body
surface area, a dose of 100 mg kg-1 in the mouse would be equivalent to a dose of 8
mg kg-1 in humans. This dose would result in a uridine exposure of 3 mg kg-1, which
is much lower than pharmacologic doses ranging from 150 to 1,000 mg kg-1 d-1
currently used to treat human diseases. The production of uridine can also decrease
the efficacy of fluoropyrimidines like 5-fluorouracil.22 While uridine levels were not
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assessed, zeb did decrease the activity of 5-fluorouracil against human oral squamous
cell carcinoma cell lines in vitro when the two drugs were combined.23
While exposure to uridine is unlikely to pose a significant risk, the production
of hydrogen peroxide when AO converts zeb to uridine may pose a risk. In all
species that express AO, its activity is highest in the liver.22 Elevations in ALT and
LDH were detected in male cynomolgus monkeys treated with zeb to achieve plasma
concentrations of 10 to 15 µM. Zeb was lethal in cynomolgus monkeys treated to
target plasma concentrations of 25 to 50 µM or with bolus intravenous injections
greater than 500 mg kg-1. In these monkeys, zeb plasma concentrations rapidly
increased prior to death, suggesting that liver or renal injury resulted may have
decreased zebularine clearance. Bolus intravenous dosing of ≤ 250 mg kg-1 did not
result in any deaths, but elevations in hepatic and renal parameters were detected.21
Production of large amounts of hydrogen peroxide resulting in massive hepatocellular
injury could account for the apparent liver injury observed in monkeys.
If differences in AO activity were responsible for differences in toxicity, then
a difference in toxicity would be expected in mice since there is a 50-fold difference
in AO activity between the sexes. While no difference in toxicity has been detected
between male and female mice, differences were detected in tumor prevention in Min
mice. Following treatment with zeb, the number of tumors that develop in female
mice is significantly decreased, but not in male mice.13 The implication of the lack of
AO activity in the dog is unclear, as is the true cause of the hepatic toxicity in
monkeys. It is unknown whether or not similar toxicity would be observed in dogs or
humans treated with zeb.
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2.10 Invasive transitional cell carcinoma in man and the dog
Around the world, human bladder cancer accounts for 3.3% of newly
diagnosed cases and 2.1% of all cancer deaths.24 Bladder cancer is the 5th most
common cancer diagnosed in the United States. Treatment is often very involved and
costly due to frequent tumor recurrence. While most humans develop non-invasive,
superficial bladder tumors that can be successfully treated locally by instillation of
therapeutic agents directly into the bladder or transurethral tumor resection, some will
go on to develop muscle InvTCC. Others will have invasive cancer already present at
diagnosis.25 In 2008, an estimated 386,300 new cases of bladder cancer were
diagnosed, and 150,200 people died due to bladder cancer around the world.26 More
than 14,000 people in the United States died due to InvTCC in 2011.27
In contrast to humans in which lower grade superficial bladder tumors
predominate, InvTCC is the most common cancer affecting the urinary tract in the
dog.28 While the true prevalence is unknown, InvTCC is estimated to account for up
to 2% of all canine cancers.27,28 Risk factors for the development of InvTCC in the
dog include use of older generation topical insecticides and dips, obesity, female sex
and breed.28 Scottish Terriers are at a 20-fold increased risk.28 Exposure of Scottish
Terriers to phenoxy herbicides like 2,4-D further increases the risk of InvTCC.29
Other breeds including Beagles, Shetland Sheepdogs, Wire Hair Fox Terriers and
West Highland White Terriers are also at an increased risk. Half or more of dogs
diagnosed with InvTCC will develop distant metastasis by the time of death. The
most common sites of metastasis are the lungs and regional lymph nodes. Death
often occurs prior to the development of metastasis due to urinary tract obstruction.28
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Dogs with naturally occurring InvTCC offer a highly relevant model of
aggressive bladder cancer in humans due to similar clinical, cellular and biological
features, and responses to chemotherapy.27,30 Most InvTCC-related deaths in dogs
and humans are due to non-resectable chemotherapy-resistant cancer. Developing
novel strategies to improve treatment efficacy is essential for both dogs and humans.
Overexpression of genes including bFGF, COX1 (PTGS1) and COX2 (PTGS2) and
mutations in TP53 are present in both human and canine InvTCC.30
While the methylation patterns in canine InvTCC have not been investigated27,
methylation patterns in human superficial bladder cancer and InvTCC have been
investigated. The development of bladder cancer in humans is known to involve
multiple oncogenes and tumor suppressor genes, including FGFR3, HRAS, CDH1,
CDKN2A (p16INK4a and p14ARF), HOXB2, RASSF1A, RB1, SFRP2 and
WAF1.25,30,31 DNA hypermethylation is known to cause transcriptional silencing of
many of these genes in human bladder cancer.30 Hypermethylation of specific genes
is frequently reported in human bladder cancer, but with inconsistent results.32 For
example, Zhu et al. reported hypermethylation of MLH1, HOXA9, SLT2 and HIC-1 in
a variety or bladder carcinomas compared to adjacent normal tissues, but were unable
to demonstrated hypermethylation of RASSF1A, MGMT and p16, which had
previously been reported. Other changes important in urothelial carcinogenesis
include deletions of chromosome 9 and defects in p53.31 Global hypomethylation is
more consistently reported in human bladder cancers, which may result in, or reflect,
genomic instability.32
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Specific methylation patterns are not consistent across all human bladder
tumors, but methylation status is associated with advanced tumors and tumor
progression. Yates et al. investigated promoter methylation within 17 genes from 96
malignant urothelial cancers and 30 normal samples. Statistically significant higher
rates of methylation were detected in eight of 17 genes (WIF-1, TNFRSF25, EDNRB,
APC, MGMT, BCL2, hTERT, IGFBP3) for malignant tumors versus normal tissue.
No statistically significant differences were detected for RASSF1A, DAPK, RARβ,
CYCLIND2, TIMP3 and HIC-1 or CDH1, CDH4 and P16 after applying Bonferonni’s
correction. Methylation at these 17 loci was significantly increased in poorly
differentiated urothelial cancers compared to well-differentiated tumors, and invasive
tumors compared to superficial tumors. Tumors that had methylated TNFRSF25,
EDNRB, RASSF1A, APC and CDH1 were significantly more likely to progress to a
more aggressive stage of disease and result in patient death. No tumors that lacked
methylation or had methylation of one gene progressed. Patients could be stratified
based on their risk of developing disease progression using subsets of these genes,
suggesting that assessment of methylation status may be useful in determining what
patients should undergo more vigilant monitoring.33 The ability to predict which
patients are unlikely to develop tumor recurrence could result in significant cost
savings, and direct resources toward patients more likely to develop tumor recurrence.

2.11 Investigation of DNMT1 in canine InvTCC cell lines
Expression of DNMT1 has been demonstrated in human InvTCC and other
cancers. Dhawan et al. demonstrated that DNMT1 is also upregulated in canine
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InvTCC.27 Microarray gene expression profiling demonstrated a 2.28-fold increase in
DNMT1 expression in biopsy samples from four dogs with InvTCC compared to
samples of bladder mucosa from four normal dogs. Positive DNMT1
immunoreactivity (>10% of cells with positive nuclear staining) was detected in 45%
(n=10) of canine biopsy samples and no immunoreactivity was detected in bladder
samples from normal dogs (n=6).27 DNMT1 would be expected in a greater
proportion in rapidly proliferating tissues as it is highly expressed during S-phase.
Increased DNMT1 expression in canine InvTCC appeared to be a rational
target for treatment with DNMT1 inhibitors, and further investigation was performed
in three canine InvTCC cell lines (K9TCC, K9TCC-PU-Sh, K9TCC-PU-Nk). Cell
lines were treated with the DNMT inhibitor 5-Aza-CR, the histone deactylase
inhibitor trichostatin A or the combination. Treatment with trichostatin A alone
resulted in morphologic changes in all three cells lines. Treatment with either 5-AzaCR or trichostatin A resulted in decreased cell counts, but the combination resulted in
a larger decrease. Decreased DNMT1 protein was detected by Western blot in two of
three cell lines (K9TCC and K9TCC-PU-Sh) following treatment with 5-Aza-CR.
Decreased DNMT1 protein was detected in all cell lines following treatment with
trichostatin A.27
Following treatment with 5-Aza-CR, p16 was slightly increased in all three
cell lines, and p21 was decreased in one cell line (K9TCC-PU-Sh). Following
treatment with trichostatin A or combination 5-Aza-CR and trichostatin A, there was
increased expression of p16 and decreased expression of cyclin D1, p21, pRb,
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survivin & PARP in all three cell lines. Expression of p16 was slightly greater
following combination treatment in K9TCC than with trichostatin A alone.27
The p16 gene is often silenced by hypermethylation in human cancers, and
therefore, the increase in p16 protein following treatment of canine InvTCC cell lines
with 5-Aza-CR, TSA or the combination is of considerable interest. These results
suggest that while the DNMT inhibitor 5-Aza-CR has some activity alone, the
addition of an HDAC inhibitor like TSA may yield better results. As the safety,
toxicity and efficacy of most DNMT inhibitors and HDAC inhibitors have not been
assessed in dogs with cancer, further investigation of these agents alone and then in
combination is indicated.27

2.12 Investigation of 5-Aza-CR in dogs with InvTCC
A phase I study of subcutaneous 5-Aza-CR was performed in dogs with
naturally occurring InvTCC to determine if further studies should be performed in
humans with InvTCC. This dog study was performed to assess toxicity, antitumor
activity and a dose range for subsequent work. 5-Aza-CR was administered
subcutaneously once daily for five days once every 14 days or 28 days. Dogs were
initially treated with a dose of 0.2 mg kg-1 per day, which is equivalent to 10% of the
FDA approved dose of 5-Aza-CR for the treatment of myelodysplastic syndrome in
humans. Dose-limiting toxicity (DLT) was defined as any grade 3 or 4 Veterinary
Cooperative Oncology Group common terminology criteria for adverse events v1.1
(VCOG-CTCAE v1.1) adverse event, and the maximum tolerated dose (MTD) was
defined as the dose at which no more than one out of six dogs within a cohort
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experienced a DLT. A total of 19 dogs were enrolled. One dog was excluded from
evaluation of tumor response due to concurrent non-steroidal anti-inflammatory drug
(NSAID) administration. Eleven dogs were treated for five consecutive days once
every 28 days, and eight dogs were treated for five consecutive days once every 14
days. Of the dogs enrolled, 73% had failed prior therapies.30
The most common adverse events following treatment with 5-Aza-CR were
myelosuppression, including grade 3 or 4 neutropenia, and gastrointestinal upset,
including grade 3 or 4 nausea and anorexia. The MTD was determined to be 0.1 and
0.2 mg kg-1 per day when 5-Aza-CR was given for five consecutive days once every
14 days or 28 days, respectively. Decreased tumor volume was detected in 55.6%
(n=10) of dogs, and 22.2% (n=4) achieved partial remission (PR; ≥50% or greater
decrease in tumor volume). While no complete remissions (CR; complete resolution
of all lesions) were detected, the disease control rate, defined as the combination of
CR, PR and stable disease (SD; <50% increase or decrease in tumor volume for at
least 8 weeks), was 72.2% (n=9).30
Samples of peripheral blood mononuclear cells (PBMCs) and bladder tumor
tissue were collected for gene-specific (CDKN2A/p14ARF) and global methylation
assays. No significant differences in global DNA methylation were detected in paired
pre- and post-treatment PBMCs from 12 dogs. Non-statistically significant decreases
in global DNA methylation ranging from 0.74% to 8.43% were detected in six dogs.
No significant differences in global DNA methylation were detected in paired preand post-treatment tumor biopsy samples from 10 dogs. Non-statistically significant
decreases in global DNA methylation ranging from 1.55% to 17% were detected in
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seven dogs. A 6.8% decrease in CDKN2A (p14ARF) methylation was detected in one
dog that achieved PR and had paired tumor samples for analysis.30
Treatment with 5-Aza-CR was generally well tolerated in dogs with InvTCC,
with reversible myelosuppression and gastrointestinal toxicity as the most clinically
relevant toxicity. While no complete remissions were detected, the overall response
rate of 72.2% and observation of a decrease in tumor volume in 56% of dogs was
promising, particularly when taking into account that 73% of treated dogs had failed
prior therapy. The lack of statistically significant DNA hypomethylation and
myelosuppression observed in this study may indicate that the tumor responses
observed were due to cytotoxic effects as opposed to demethylating activity.
Cytotoxicity is known to occur at some doses of 5-Aza-CR, and these doses have not
been well defined in the dog. Similarly, tumor responses without detectable changes
in DNA methylation have been observed in human cancers treated with drugs thought
to work through DNA demethylation. The optimal timing of post-treatment sample
collection is unknown, and the lack of significant changes could reflect that samples
were not collected at the optimal time interval after initiating demethylating therapy.30
Another possible explanation for lack of detection of gene-specific hypomethylation
is inappropriate target selection. CDKN2A (p14ARF) is frequently lost through
deletions in human bladder cancer 32, thus it may not even be present to undergo
demethylation. Similarly, genes other than CDKN2A (p14ARF) may have undergone
gene-specific hypomethylation, but were not investigated.
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2.13 Conclusion
Investigation of demethylating agents is just beginning in pet dogs. Treatment
of dogs with InvTCC 5-Aza-CR was generally well tolerated and had a promising
disease control rate of 72.2%.30 Canine InvTCC cell lines appear to have increased
activity of DNMT1 that can be impaired by treatment with 5-Aza-CR, TSA or the
combination.27 These studies provide a basis for the further exploration of
demethylating therapy in pet dogs with InvTCC. While 5-Aza-CR has shown
promise, treatment involved frequent subcutaneous injections.30 Zeb’s stability offers
a significant advantage over 5-Aza-CR2,3,4,17, particularly in the treatment of pet dogs,
because it can be easily administered orally on a continuous schedule. Despite its
apparent low bioavailability in the initial pharmacokinetic study20, zeb was the first
agent to demonstrate in vivo demethylating activity following oral administration.17
Zeb was well tolerated in rodents, but marked hepatic toxicity and death were
reported following high dose treatment in male cynomolgus monkeys.21 The cause of
toxicity in cynomolgus monkeys is unknown, but the use of such high doses of zeb in
the future would be unlikely.
To the author’s knowledge, prior to the work described in the following
chapters, no in vivo evaluation of zeb has been performed in the dog. The purpose of
the work described in the following chapters was to evaluate the pharmacokinetics
and toxicity of zeb in laboratory dogs and tumor bearing dogs, and provide an initial
description of zeb’s activity in dogs with InvTCC.
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CHAPTER 3. PHARMACOKINETICS AND TOXICITY OF THE NOVEL ORAL
DEMETHYLATING AGENT ZEBULARINE IN LABORATORY AND
TUMOR BEARING DOGS
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Abstract

The purpose of this study was to determine the plasma pharmacokinetics and toxicity of
zebularine (zeb), an oral cytidine analog with demethylating activity, in dogs. Plasma
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zeb concentrations were determined by HPLC-MS/MS following an oral zeb dose of 8 or
4 mg kg-1. Plasma zeb clearance was constant. Mean Cmax was 23 ± 4.8 and 8.6 ± 1.4
µM following 8 and 4 mg kg-1, respectively. Mean half-life was 5.7 ± 0.84 and 7.1 ± 2.1
following 8 and 4 mg kg-1, respectively. A single 8 mg kg-1 dose was well tolerated.
Daily 4 mg kg-1 treatment in 3 laboratory dogs resulted in grade 4 neutropenia (n=3),
grade 1 anorexia (n=2) and grade 1 or 2 dermatologic changes (n=2). All adverse events
resolved with supportive care. A 4 mg kg-1 dose every 21 days was well tolerated. A
follow up dose escalation study is in progress with a lower starting dose.

3.3

Introduction

DNA methylation is an important epigenetic modification that often occurs on
cytosines within cytosine guanine dinucleotides (CpGs).1,2 CpGs are concentrated within
gene promoter regions in half of all human genes.1 Hypermethylation of DNA within the
promoter region of a tumor suppressor gene can result in functional silencing of the gene
and an increased risk of cancer development or progression. DNA methylation patterns
are maintained by DNA methyltransferases (DNMTs) during DNA replication. Unlike
genetic mutations, epigenetic changes are potentially reversible.1,2
Zeb (1-β-D-Ribofuranosyl-2(1H)-pyrimidinone) is a cytidine analog that was
originally identified as a bacteriostatic drug, then determined to be a cytidine deaminase
(CDA) inhibitor and more recently determined to be a DNMT inhibitor.2,3 Zeb is
incorporated into DNA in place of cytidine and forms a complex with DNMTs, thus
inhibiting methylation. The mechanism of action of zeb’s demethylating activity is
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similar to that of 5-azacytidine (Vidaza®, Celgene Corp., Summit, NJ, USA; 5-Aza-CR)
and decitabine (Dacogen®, SuperGen, Inc., Dublin, CA, USA; 5-Aza-CDR), which are
currently FDA approved for the treatment of human cancers.3 Unlike 5-Aza-CR and 5Aza-CDR, zeb is stable at a broad pH range and is not subject to rapid inactivation by
CDA.2,3 In addition, zeb acts as a radiosensitizer in vitro, which may be due to inhibition
of DNA repair.4,5
Dogs with naturally occurring cancer offer an excellent opportunity to evaluate
and optimize new cancer treatment strategies including those involving demethylating
agents.6,7 The injectable DNMT inhibitor 5-Aza-CR has been investigated in dogs with
invasive transitional cell carcinoma (InvTCC) of the urinary bladder with promising
results. Subcutaneous injections were administered daily for five consecutive days at two
or four week intervals in 18 dogs, resulting in 22% partial remission and 50% stable
disease for more than eight weeks.7 Daily oral administration is likely to be the most
convenient dosing strategy and potentially the most efficacious since demethylating
agents requires actively dividing cells, making zeb an attractive drug to investigate in
subsequent studies.8,9
Previous pharmacokinetic and toxicity assessment of zeb has been performed in
mice, rats and rhesus monkeys.10 Zeb administered by intravenous or intraperitoneal
injection, oral gavage or in drinking water was well tolerated in vivo in genetically tumorprone mice, transgenic mice and mice harboring tumor xenografts. Demethylating
activity correlated with tumor responses including stable disease, delayed or decreased
tumor development and decreases in tumor volume compared to untreated control
mice.11-16 Following very high dose zeb treatment in cynomolgus monkeys,
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clinicopathologic evidence of liver and kidney injury were detected. Further dose
elevations were lethal.17
In vivo evaluation of zeb has not been performed in the dog. Previous study in the
dog is limited to an in vitro zeb plasma protein binding assay performed on samples from
Beagle dogs.10 The purpose of this study was to evaluate the pharmacokinetics and
toxicity associated with oral zeb administration in laboratory dogs and dogs with
naturally occurring cancer.

3.4

Materials and Methods

Study subjects
All work was approved by the Purdue Animal Care and Use Committee.
Laboratory dogs were obtained from Marshall Farms (North Rose, New York, USA) and
then housed and evaluated in the Clinical Discovery Laboratory, College of Veterinary
Medicine, Purdue University. Privately owned, tumor bearing dogs undergoing treatment
at the Purdue University Veterinary Teaching Hospital (PUVTH) were enrolled following
informed written pet owner consent. Entry criteria included a definitive diagnosis of
cancer via histopathology, measurable cancer and expected survival time of at least 6
weeks. Dogs were allowed to enroll if they had failed other cancer therapy or if other
therapy had been declined for any reason. Dogs were allowed to continue non-steroidal
anti-inflammatory drugs (NSAIDs) if needed for pain control, and if cancer progression
had been documented during NSAID treatment prior to zeb administration. Tumor
bearing dogs lived at home with their owners, and were evaluated at the PUVTH.
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Zebularine formulation
Pharmaceutical grade zeb was provided through the National Cancer Institute’s
Experimental Therapeutics (NExT) Program as a bulk powder. Zeb was compounded
into gelatin capsules in sizes ranging from 5 to 20 mg by Diamondback Drugs, LLC
(Scottsdale, AZ, USA).

Zebularine plasma pharmacokinetics
Plasma pharmacokinetic analysis was performed in samples from dogs following
a single oral dose of 8 mg kg-1 or 4 mg kg-1 with food. Laboratory dogs (n=3) received 8
mg kg-1, and pet dogs received 4 mg kg-1. Doses were rounded to the nearest 5 mg due to
capsule size. Serial venous blood samples were collected prior to the first treatment and
at 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 hours following zeb administration to obtain the
plasma concentration versus time profile. Following collection into ethylenediaminetetraacetic acid (EDTA) blood collection tubes, blood samples were immediately
centrifuged (1,800 g, 15 min, 4°C), and plasma was collected. Samples were stored at
-80 °C until analysis.
Analyses were performed by the Clinical Pharmacology Analytical Core Facility
at Indiana University School of Medicine, Indianapolis, IN, USA. Zeb was quantified in
plasma using 5-Aza-CR as the internal standard, liquid-liquid extraction, and HPLCMS/MS (Thermo Accela pump and Thermo TSQ Quantum Ultra MS/MS; Thermo
Fisher). Zeb and 5-Aza-CR were separated by gradient mobile phase (acetonitrile:5mM
ammonium formate) and HPLC using a C8 column (Zorbax, 5 µm 250 X 4.6 mm). The
Q1/Q3 settings (in positive mode) for zeb and 5-Aza-CR were 229/97 and 245/113,
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respectively. The lower limit of quantification (LOQ) is 1 ng mL-1 using 200 µL of
plasma.
Pharmacokinetic parameters for zeb including area under the curve (AUC), area
under the moment curve (AUMC) and the elimination rate constant, kel, were estimated
using noncompartmental methods with add-ins on Excel®. The half-life (t1/2) was
estimated by 0.693 kel-1. Zeb AUC was estimated from time zero to infinity. The AUC
from the last concentration, Clast, to infinity was estimated by Clast kel-1. The systemic
clearance (Cl F-1, where F is the bioavailability) was calculated from the dose and
AUC0-∞ and the volume of distribution at steady state (Vdss F-1) was calculated from the
Cl and the mean residence time (MRT; MRT =(Dose/AUC)x(AUMC/AUC). The
maximum plasma concentration (Cmax) and the time of Cmax (tmax) were obtained from the
data.

Zebularine toxicity
Zeb toxicity was assessed following daily oral dose of 4 mg kg-1 in laboratory
dogs and an oral zeb dose of 4 mg kg-1 once every 21 days in tumor bearing dogs.
Toxicity was assessed by physical examination, serial complete blood counts and serial
serum biochemistry panels. Serial complete blood counts and serum biochemistry panels
were initially planned weekly and then performed as needed based on observed toxicity
at the discretion of the attending clinician. Toxicity was graded using the Veterinary
Cooperative Oncology Group common terminology criteria for adverse events v1.1
(VCOG-CTCAE v1.1).18
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3.5

Results

Study subjects
Three laboratory dogs of approximately one year of age (one male intact Beagle,
one female intact Beagle, and one female intact mixed breed dog) were enrolled. The
dogs weighed 11.4, 7.7 and 16.9 kgs respectively. Initial pharmacokinetics assessment
was performed following a single oral dose of approximately 8 mg kg-1 (range 7.8 to 8.0
mg kg-1), and toxicity assessment was performed following daily dosing of approximately
4 mg kg-1 (range 3.8 to 3.9 mg kg-1).
Three tumor bearing dogs (one 8.7 year old male neutered Beagle, one 9.6 year
old male neutered mixed breed dog, and one 11.3 year old female spayed Labrador
retriever) were enrolled. The dogs weighed, 16.9, 27.9 and 30.6 kgs, respectively. Two
tumor bearing dogs had a histopathological diagnosis of InvTCC, and one had a diagnosis
of a recurrent gastrointestinal stromal tumor (GIST). One dog with InvTCC had been
previously treated with an NSAID (carprofen) for pain and continued to receive an
NSAID (piroxicam) at the time of enrollment. One dog with InvTCC had previously
failed one injectable chemotherapy drug (vinblastine) and one NSAID (firocoxib). The
dog with GIST had undergone surgery to remove the tumor, and the tumor recurred seven
months later at the time zeb was initiated. Pharmacokinetics assessment in these dogs
was performed following the initial oral dose of approximately 4 mg kg-1 (range 3.8 to
3.9 mg kg-1). The dogs continued to receive this dose at 21 days intervals for toxicity
assessment.
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Zebularine pharmacokinetics
Pharmacokinetics results are summarized in Table 3.1 and zeb concentration
versus time curves are shown in Figure 3.1. Following an oral dose of 8 mg kg-1, the
mean tmax was 1.2 ± 0.62 hours, mean t1/2 was 5.7 ± 0.84 hours, mean Cmax was 5280 ±
0.84 ng ml-1, and mean AUC0-∞ was 35,358 ± 6132.6 ng ml-1. Following an oral dose of
4 mg kg-1, the mean tmax was 2.3 ± 1.2 hours, mean t1/2 was 7.1 ± 2.1 hours, mean Cmax
was 1962 ± 320.3 ng ml-1, and mean AUC0-∞ was 17,206 ± 3221.4 ng ml-1.

Zebularine toxicity – laboratory dogs treated daily with 4 mg kg-1 zebularine
All three laboratory dogs treated with a daily oral zeb dose of 4 mg kg-1
developed grade 2 (n=1) or grade 3 (n=2) neutropenia that progressed to grade 4
neutropenia. Zeb was discontinued when grade 2 or greater neutropenia was detected on
day 14 (n=1), day 23 (n=1) and day 24 (n=1). Neutropenia progressed to grade 4
neutropenia by day 21 (n=1), day 29 (n=1) and day 30 (n=1). Grade 1 thrombocytopenia
was detected in one dog. Grade 1 anorexia was detected immediately prior to grade 4
neutropenia in two dogs. No abnormalities were detected in serial serum biochemistry
panels. After marked neutropenia developed, supportive care was initiated including
antibiotics (n=3), antiemetics (n=2) and intravenous crystalloid fluids (n=2). All three
dogs recovered, and neutrophil counts returned to normal within 16, 17 or 19 days,
respectively. No abnormalities were detected in serial serum biochemistry panels.
Intermittent dermatologic changes were detected in two laboratory dogs including
grade 2 rash/desquamation in the axilla (n=1) and grade 1 erythema of ventral abdomen
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(n=1). Dermatologic changes resolved without specific treatment after zeb was
discontinued.
The laboratory dogs underwent orchiectomy (n=1) or laparoscopic
ovariohysterectomy (n=2), and had laparoscopic liver and kidney biopsies (n=3)
performed prior to placement in permanent private homes. Specific pathology was not
detected in any of the samples that were collected. Liver biopsies revealed non-specific,
mild to moderate, reversible, hepatocellular degeneration in one dog and mild hydropic
change in one dog. Renal pathology was not observed.

Zebularine toxicity – tumor bearing dogs treated once every 21 days with 4 mg kg-1
zebularine
Three tumor bearing dogs received six, four, and one dose(s) of zeb, respectively.
Grade 1 thrombocytopenia was detected one week after the first zeb treatment in one dog.
No dose adjustment was made, and thrombocytopenia did not recur. No other
hematologic abnormalities, serum biochemical abnormalities or dermatologic changes
were detected.

3.6

Discussion

The purpose of this study was to determine the plasma pharmacokinetics and
assess toxicity of the novel demethylating agent, zeb, in laboratory and tumor bearing
dogs. The work builds upon that previously reported in mice, rats, and monkeys, and
provides pivotal information required for subsequent investigation of zeb’s potential as a
demethylating and antineoplastic agent in dogs.10-16 Knowledge of the peak plasma

44
concentrations in dogs can be taken into account when interpreting in vitro and in vivo
mechanisms studies. The constant plasma clearance and half-life of approximately four to
nine hours, can be used in designing subsequent treatment studies in dogs. Epigenetic
based treatment strategies can be applied across several cancer types, but work in
naturally occurring canine InvTCC is particularly intriguing as it serves as a relevant
model of the cancer in humans. Studies in dogs are expected to lead to the development
of new treatment strategies that can be applied in both species.6
The dog study contributed to the understanding of the potential toxicity of zeb.
Following daily treatment with 4 mg kg-1 zeb, grade 4 neutropenia developed in all three
laboratory dogs. Although the myelosuppression resolved after zeb was discontinued,
and all dogs recovered with supportive care, clearly lower zeb doses are indicated for
follow-up studies. The myelosuppression in dogs was not completely unexpected as this
has occurred with other demethylating agents in dogs and humans, especially when the
drugs are given at higher, cytotoxic doses.7,19 The degree of hematologic toxicity at the 4
mg kg-1 dose in dogs, however, was not expected when considering the available
published in vivo study results of zeb in other species. Zeb was reported to be well
tolerated in mice with no significant weight loss or mortality when administered for
weeks to months.11-15 Although clinicopathologic assessments were not reported in the
mouse studies, it would be expected that should severe myelosuppression have occurred,
that infection and sepsis would have been noted in the mice. It is also possible that higher
doses of zeb in mice could result in myelosuppression. In male cynomolgus monkeys
treated with five out of seven day intravenous infusions of zeb at <250 mg kg-1 per day
for two consecutive weeks, an elevation in white blood cell count was observed, although
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it is not known if the blood counts were performed when the neutropenia would have
occurred if it were going to occur at that dosage. Regardless of whether the findings in
dogs were expected or not, the documentation of the reversible, yet severe,
myelosuppression in dogs is being used in the planning of additional studies of zeb in
dogs. A dose of 4 mg kg-1 every 21 days resulted in no appreciable toxicity in tumor
bearing dogs. A follow-up dog study is in progress in which the dose intensity of the
starting dose cohort (daily 0.2 mg kg-1 zeb) is equivalent to the dose intensity of 4 mg kg1

once every 21 days. This daily dose has been well tolerated to date in dogs.
The dog study results were encouraging in that major internal organ toxicity was

not observed in dogs at any of the doses given. There has been concern for liver and
kidney toxicity of zeb in other species. In male cynomolgus monkeys treated with five
out of seven day intravenous infusions at 250 mg kg-1 per day of zeb for two consecutive
weeks, clinicopathologic changes included elevated alanine aminotransferase (ALT),
lactate dehydrogenase (LDH) and creatine kinase (CK). Higher zeb doses of 500, 750 or
1,000 mg kg-1 given by continuous infusion or bolus resulted in lethal toxicity.17 Zeb
plasma concentrations rapidly increased prior to death in the cynomolgus monkeys
treated with very high dose zeb, raising the possibility that liver or renal injury could
have resulted in decreased zeb clearance.17 While LDH and CK were not assessed in the
current dog study, serum biochemistry panels did not reveal any evidence of liver or
kidney injury following zeb treatment. Evaluation of post-treatment liver and kidney
biopsies did not reveal any specific pathologic changes.
Differences in aldehyde oxidase (AO) activity or other not-yet-characterized
enzymes involved in the metabolism of zeb could account for variation in drug
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metabolism, efficacy and toxicity across species and individuals.3,20,21 Among hepatic
cytosol samples from mice, rats, humans and a male cynomolgus monkey, AO activity
was highest in male mice and lowest in female mice. AO activity was not detected in
hepatic cytosol from a male Beagle dog. A 50-fold difference was detected between
male and female mice, but a similar magnitude of difference was not detected between
sexes in rats or humans.22 There is often greater aldehyde oxidase homology between
mice and humans than monkeys and humans.3 The effect of differential AO activity may
account for differences in the effects of zeb on tumor development between female Min
mice and male Min mice. These mice harbor a defect in the adenomatous polyposis coli
(APC) gene that leads to development of benign intestinal adenomas. The number of
tumors that developed in female, but not male, Min mice significantly decreased
following treatment with zeb. In Min mice, there were no reported sex differences in zeb
toxicity.16 The lack of AO activity in the dog could result in improved bioavailability due
to a decrease in first pass metabolism.
While tumor response was not a primary end point of this study, and a very small
tumor bearing cohort of dogs was evaluated, it was noted that the two dogs with InvTCC
treated with zeb had stable disease (<50% change in tumor size and no new lesions) when
treated with zeb once every 21 days for 12 to 18 weeks. In dogs that have failed therapy
with progressive disease, InvTCC often progresses rapidly, and lack of progression over
3-4 months suggests beneficial drug activity. In addition, when considering that the
optimal dosing strategy for demethylating agents is likely daily administration7,9, the
dosing strategy employed in tumor bearing dogs was unlikely to reflect the optimum
benefit that could be gained from zeb. It is also important to note that the demethylating

47
effects of zeb could occur at doses considerably lower than those which were toxic in
dogs.3 With a half-life in the dog ranging from approximately four to nine hours, near
continuous exposure to zeb would be expected even with dosing once every 24 hours.
Furthermore, the production of stable zeb metabolites may act as a depot for the drug,
allowing for drug accumulation and recycling.23
In summary, this study provided important information concerning the
pharmacokinetics and toxicity of zeb in dogs. A daily dose of zeb of 4 mg kg-1 resulted
in unacceptable, but reversible, hematologic toxicity in laboratory dogs while a dose of 4
mg kg-1 every 21 days resulted in no appreciable toxicity in tumor bearing dogs. A daily
dose of zeb (0.2 mg kg-1), which is equivalent to the dose intensity of 4 mg kg-1 once
every 21 days, has been well tolerated in dogs to date. Continued investigation of zeb is
warranted in tumor bearing dogs to determine the optimal dosing strategy, activity as
both a single agent and in combination with other drugs and characterization of
demethylating activity in vivo.
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Table 3.1. Pharmacokinetic parameters from laboratory dogs treated with a
single oral zebularine dose of 8 mg kg-1 (n=3) and tumor bearing dogs treated
with a single oral zebularine dose of 4 mg kg-1.

Dog

Weight
(kg)

Dose
(mg)

Cmax
(ng ml-1)

Mean Cmax
(µM)

tmax
(hrs)

AUC0-∞
(ng ml-1 hr)

t1/2
(hrs)

Cl/F
(L/hr)

Vdss/F
(L)

Laboratory dogs – 8 mg kg-1
1

16.9

135

4695

--

2.0

43584

6.8

3.1

29.2

2

7.7

60

6824

23 ± 4.8

0.5

33626

5.4

1.8

12.5

3

11.4

90

4322

--

1.0

28865

4.8

3.2

21.3

Tumor bearing dogs – 4 mg kg-1
1

16.9

65

1850

--

2.0

12665

8.3

5.1

52.7

2

27.9

110

2399

8.6 ± 1.4

1.0

19167

4.1

5.7

38.6

3

30.6

120

1639

--

4.0

19788

8.9

6.1

84.1

Cmax: maximum concentration
tmax: time of maximum concentration
AUC0-inf: area under the plasma concentration-time curve from 0-infinity
t1/2: half-life
Cl/F: clearance/availability; if dosage is IV, then F=1
Vd/F: apparent volume of distribution
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A

B
Figure 3.1. Zeb clearance in three laboratory dogs following a single oral dose of
8 mg kg-1 (A) and three tumor bearing laboratory dogs following a single oral
dose of 4 mg kg-1 (B).
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CHAPTER 4. PHASE I DOSE ESCALATION TRIAL OF THE ORAL
DEMETHYLATING AGENT ZEBULARINE IN DOGS WITH INVASIVE
TRANSITIONAL CELL CARCINOMA
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4.2

Abstract

A phase I clinical trial of zebularine (zeb) was performed in dogs with naturally occurring
invasive transitional cell carcinoma (InvTCC). A total of 26 dogs were enrolled in six
treatment cohorts ranging from 0.2 to 0.7 mg kg-1 per day. Dose-limiting toxicity (DLT)
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included neutropenia following a daily zeb dose of 0.6 mg kg-1. Based on results to date,
the maximum tolerated dose (MTD) is likely to be 0.5 mg kg-1 per day. Of the 26 dogs
treated, 73% had failed treatments including NSAIDs, oral and injectable chemotherapy.
Median progression free survival was 86 days (95% CI, 47.5-124.5). Of 19 dogs
evaluated for tumor response, 14 had stable disease for at least eight weeks, and five had
progressive disease. Zeb was well tolerated up to 0.5 mg kg-1 per day and further
investigation of zeb alone or in combination in the dog should be targeted at this dose.

4.3

Introduction

Zeb is an oral demethylating agent with the potential to reactive silenced genes in
cancer.1-5 Our group performed an initial investigation of the pharmacokinetics and
toxicity of zeb in laboratory and tumor bearing dogs. A zeb dose of 8 mg kg-1 per day in
laboratory dogs resulted in remarkable but reversible neutropenia. A zeb dose of 4 mg
kg-1 once every 21 days was well tolerated in tumor bearing dogs (see Chapter 3). A
daily dosing schedule has been proposed as the optimum dosing strategy for
demethylating agents.6,7
Naturally occurring InvTCC in the dog is an excellent model of the disease in
humans and has previously been used in the study of the injectable demethylating agent
5-Aza-CR with promising results.8,9 The purpose of this study was to perform a phase I
trial of zeb in dogs with naturally occurring InvTCC.
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4.4

Materials and Methods

Study subjects
All work in pet dogs was approved by the Purdue Animal Care and Use
Committee. Privately owned dogs with a histopathological diagnosis of invasive
transitional cell carcinoma undergoing treatment at the Purdue University Veterinary
Teaching Hospital (PUVTH) was enrolled following informed written pet owner consent.
Entry criteria included a definitive diagnosis of InvTCC via histopathology, measurable
disease and an expected survival time of at least eight weeks. Dogs were allowed to
enroll if they had failed other cancer therapy or if other cancer therapy had been declined
for any reason. Dogs that had previously been treated with non-steroidal antiinflammatory drugs (NSAIDs) and had documented evidence of cancer progression were
allowed to continue on NSAIDs after starting zeb. Dogs lived at home with their owners
and were regularly evaluated at the PUVTH.

Dog monitoring and evaluation
Physical examination was scheduled at least monthly at the PUVTH and weekly
at the dogs’ local veterinary hospitals. Serial complete blood counts (CBC) were
scheduled weekly and then biweekly, or more often at the discretion of the attending
veterinarian based on observed toxicity. Serial serum biochemistry panels were
scheduled monthly, or more often at the discretion of the attending veterinarian based on
observed toxicity. All toxicity was graded using the Veterinary Cooperative Oncology
Group common terminology criteria for adverse events v1.1 (VCOG-CTCAE v1.1).10
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Staging tests including three view thoracic radiographs and complete abdominal
ultrasound were scheduled at eight-week intervals. Ultrasound of the urinary tract using
a previously published protocol was performed once every four weeks.11 Urinary bladder
ultrasound was performed by a single operator (DWK) when the urinary bladder was
distended to a similar volume as the previous exam. Dogs were placed in right lateral
recumbency, and measurements were recorded. Bladder tumor volume was estimated by
multiplying the lesion area in the sagittal plane by the dorsal-ventral dimension in the
transverse plane measurement and sagittal plane measurement.11 Tumor response was
defined as complete remission (CR) if there was complete resolution of all lesions, partial
remission (PR) if there was ≥50% decrease in tumor volume but not complete resolution
of all lesions, stable disease (SD) if there was <50% increase or decrease in tumor
volume for at least eight weeks and progressive disease (PD) if a ≥50% increase in tumor
volume was detected or new lesions developed.

Zebularine peak and trough concentration
After at least four weeks of zeb treatment, peak (two hours after an oral zeb dose
with food) and trough (approximately 24 hours after the last zeb dose) blood samples
were collected into ethylenediaminetetraacetic acid (EDTA) blood collection tubes and
immediately centrifuged (1,800 g, 15 min, 4°C). Plasma was collected and stored at 80°C until analysis. Analysis to determine the plasma zeb concentration was performed
by the Clinical Pharmacology Analytical Core Facility at Indiana University School of
Medicine, Indianapolis, IN, USA as described in Chapter 3.
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Zebularine formulation
Zeb was provided by the National Cancer Institute’s Experimental Therapeutics
(NExT) Program as a bulk powder and compounded into gelatin capsules from 0.5 to 20
mg by Diamondback Drugs, LLC (Scottsdale, AZ, USA).

Zebularine dose escalation
Pet dogs received an initial zeb dose of 0.2 mg kg-1 per day in food based on the
data presented in Chapter 3. Enrollment of a minimum of three dogs per cohort was
planned with dose escalation of 0.1 mg kg-1 per cohort. DLT was defined as any grade 3
or greater adverse event as described by VCOG-CTCAE v1.11.10 Dose cohorts were
expanded to include at least six dogs if a DLT was observed. MTD was defined as the
dose at which a DLT occurred in no more than one of six dogs within a cohort.
Treatment with zeb was continued as long as there was evidence of disease control,
defined as CR, PR or SD, was detected. Dose escalation was allowed if there was
evidence of PD or SD.

4.5

Results

Study subjects
A total of 26 dogs with InvTCC were enrolled in six treatment cohorts. There
were 17 female spayed dogs and nine male neutered dogs. Median age was 11.6 years
(range 6.8 to 17.3), and median weight was 17.5 kgs (range 3.8 to 36.7). The most
common breeds were mixed breed (n=5), Scottish Terrier (n=4), West Highland White
Terrier (n=4), Shetland Sheepdog (n=2) and Standard Poodle (n=2). Other breeds
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represented by one dog each included Australian Shepherd, Basset Hound, Beagle, Collie,
Dachshund, German Shepherd Dog, Golden Retriever, Labrador Retriever and Yorkshire
Terrier. Of the 26 dogs, 73% (n=19) had failed previous treatments including NSAIDs,
oral chemotherapy and injectable chemotherapy.
Two dose escalations were performed within one dog from 0.2 to 0.3 and then to
0.4 mg kg-1 without evidence of PD. Dose escalation was performed within one dog
from 0.3 to 0.4 without evidence of PD. Dose escalation was performed within one dog
from 0.5 to 0.6 mg kg-1 due to PD. Dose de-escalation was performed in one dog from
0.3 to 0.2 mg kg-1 due to grade 1 neutropenia. Patient characteristics for each treatment
cohort are summarized in Table 4.1.

Zebularine toxicity
Hematologic toxicity is summarized in Table 4.2. Grade 1 neutropenia (n=1) and
grade 1 thrombocytopenia (n=1) were detected in the 0.2 mg kg-1 cohort. Grade 1
neutropenia (n=1) was detected in the 0.3 mg kg-1 cohort. The dose of zeb in one dog
was de-escalated to the 0.2 mg kg-1 cohort from the 0.3 mg kg-1 cohort, but grade 1
neutropenia persisted. Grade 1 neutropenia (n=1) and grade 2 thrombocytopenia (n=1)
were detected in the 0.4 mg kg-1 cohort. Grade 1 neutropenia (n=1) and grade 1
thrombocytopenia (n=1) were detected in the 0.5 mg kg-1 cohort. Grade 3 neutropenia
(n=1), grade 1 neutropenia (n=1) and grade 2 thrombocytopenia (n=1) were detected in
the 0.6 mg kg-1 cohort.

60
Grade 2 anorexia was reported in one dog in the 0.4 mg kg-1 cohort. No other
remarkable gastrointestinal adverse events were reported that were not present prior to
starting zeb. No remarkable changes were noted in serial serum biochemistry panels.
One dog in the 0.3 mg kg-1 cohort with a history of seizures that were reportedly
well controlled with potassium bromide had one seizure approximately 24 hours after the
first dose of zeb. Zeb was discontinued, but the dog had additional seizures. An MRI
was performed and revealed a T1 and T2 hypointense intra-axial mass within the left
olfactory bulb with heterogeneous central contrast enhancement and strong peripheral
contrast enhancement. The appearance of this lesion was consistent with a meningioma.
Several dogs enrolled in the 0.6 mg kg-1 cohort and the dog in the 0.7 mg kg-1
cohort have been enrolled for less than eight weeks at the time of this analysis. While no
adverse events have been reported at the time of this analysis, these dog may not have
been enrolled for long enough to detect adverse events.

Tumor response
Of 26 individual dogs, 19 dogs have been evaluable for tumor response after at
least eight weeks of therapy. No complete or partial remissions were detected. SD was
detected in 14 dogs (73.7%), and PD was detected in 5 dogs (26.3%). Overall disease
control rate, defined as CR, PR or SD was 73.7%. Dogs were excluded from evaluation
of tumor response if there was no evidence of tumor progression but dogs had been on
treatment for less than eight weeks (n=3) or if they had stopped zeb for any reason other
than tumor progression (n=4). One dog stopped zeb after one dose due to seizures.
Subsequently, a suspected meningioma was diagnosed by MRI. One dog was euthanized
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after 40 days of zeb treatment without evidence of tumor progression due to acute hind
limb paresis due to suspected intervertebral disc disease (IVDD). IVDD was confirmed
at necropsy. One dog with a history of syncopal episodes and pancreatitis died acutely at
home after 10 days of treatment. A necropsy was declined in this case. One dog with a
history of marked anorexia prior to starting zeb treatment stopped treatment after 22 days.
Progression free survival analysis was performed using IBM’s SPSS Statistics 21.
Dogs were censored from survival analysis if they were still alive and on zeb at the time
of analysis (n=7), if zeb was stopped for any reason other than disease progression (n=4)
or if they were lost to follow up (n=1). Median progression free survival calculated using
the Kaplan Meier product limit was 86 days (95% CI, 47.5-124.5; see Figure 1).
At the time of analysis, two dogs have experienced ongoing long-term disease
stabilization. One dog experiencing SD for more than 511 days has had the dose
escalated without progressive disease from 0.2 to 0.3 and then 0.4 mg kg-1. One dog
experiencing SD for more than 182 days was treated at 0.4 mg kg-1.

Zebularine peak and trough plasma concentrations
Peak and trough plasma samples following at least four weeks of daily zeb
treatment were available from dogs treated daily with 0.2 mg kg-1 (n=6), 0.3 mg kg-1 (n=7)
and 0.4 mg kg-1 (n=1). Following daily oral zeb treatment with 0.2, 0.3 and 0.4 mg kg-1,
mean zeb peak plasma concentrations were 179 ± 50 ng ml-1 (0.78 ± 0.22 µM), 233 ± 131
ng ml-1 (1.1 ± 0.57 µM) and 292 ng ml-1 (1.28 µM), respectively. Following daily oral
zeb treatment with 0.2, 0.3 and 0.4 mg kg-1, mean zeb trough plasma concentrations were
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64 ± 17 ng ml-1 (0.28 ± 0.075 µM), 101 ± 40 ng ml-1 (0.44 ± 0.17 µM) and 67 ng ml-1
(0.29 µM), respectively.

4.6

Discussion

The purpose of this phase I trial was to determine the DLT and MTD of daily oral
zeb in dogs with InvTCC. Naturally occurring InvTCC in the dog is a relevant model of
human cancer, and discoveries in the dog can be translated into more effective treatments
in humans. Globally, 2.1% of all human cancer deaths are attributed to bladder cancer.12
Demethylating agents like 5-Aza-CR and 5-Aza-CDR are FDA approved for
myelodysplastic syndrome,2,5 and these agents are being investigated in the treatment of
solid tumors.6 Zeb was the first agent that resulted in successful demethylating activity
following oral administration.1
Overall, zeb was well tolerated in dogs with InvTCC up to 0.5 mg kg-1. Based on
previous work by our group, hematologic toxicity was anticipated as dose increased (see
Chapter 3). A DLT of grade 3 neutropenia was detected in one dog within the 0.6 mg kg1

cohort. MTD was defined as the cohort in which one of six dogs experienced a DLT.

By definition, MTD has not yet been reached at the time of this analysis. Based on
toxicity that has been observed thus far, it is likely that 0.5 mg kg-1 will be the MTD for
daily administration. Further information will be provided as dogs within the 0.5, 0.6 and
0.7 mg kg-1 cohorts continue to be evaluated.
While tumor response was not a primary outcome, the overall disease control rate
of 73.3% and median progression free survival of 86 days were promising. Given the
small sample size, the effect of censoring may impact these results, and further analysis
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when the data is more mature is indicated. Investigation of the DNA methylation
patterns in responders and non-responders may reveal a subset of patients that are more
likely to respond to demethylating therapy. Of particular interest are 2 dogs with ongoing
responses of 511 and 182 days.
Measurement of zeb plasma concentrations following chronic daily oral
administration revealed that zeb was present in the plasma at detectable levels throughout
a 24-hour period. The peak plasma concentrations of zeb were 179 ± 50 ng ml-1 (0.78 ±
0.22 µM), 233 ± 131 ng ml-1 (1.1 ± 0.57 µM) and 292 ng ml-1 (1.28 µM) following daily
oral dosing of 0.2, 0.3 and 0.4 mg kg-1, respectively. The plasma zeb concentration
achieved following treatment with daily 0.5 mg kg-1 is likely greater than 1 µM. While
these concentrations are far lower than concentrations previously investigated in vitro and
in vivo, growing evidence suggests that such high concentrations may not be necessary
for efficacy. Treatment of human hematopoietic and epithelial cancer cell lines and
derivative mouse xenografts with nanomolar doses of either 5-Aza-CR or 5-Aza-CDR
resulted in altered gene expression and DNA demethylation. At ultra low doses, 5-AzaCR and 5-Aza-CDR appear to target stem-like populations within tumors. A stem-like
population of cells would have to be depleted before a clinical response would be
observed, which could account for the observed delay between treatment initiation and
tumor response in humans with myelodysplastic syndrome.13 Zeb plasma concentrations
in the micromolar or nanomolar range are safely achievable in the dog and these
concentrations may be sufficient to achieve the desired anti-neoplastic activity without
undesirable toxicity.

64
In summary, daily treatment with zeb up to 0.5 mg kg-1 has been well tolerated in
dogs with InvTCC and resulted in a promising disease control of 73.3%. Based on initial
data analysis, the DLT of daily oral zeb is likely neutropenia at doses higher than 0.5 mg
kg-1, and MTD is likely to be 0.5 mg kg-1. A daily dose of zeb up to 0.5 mg kg-1 is a
rational starting point for investigating the potential of zeb in combination with other
cytotoxic chemotherapy agents.
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26 individual dogs were enrolled (17 FS, 9 MN; 21 pure bred dogs, 5 mixed breed dogs)
a
1 dog was dose de-escalated from 0.3 to 0.2 mg kg-1 due to grade 1 neutropenia
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c
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d
1 dog was dose escalated from 0.5 to 0.6 mg kg-1 after developing progressive disease
e
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f
Prostate involvement

Breed

TNM

# Prior
Txe

Sex
Weight

Number
Age

0.3 mg kg-1

0.2 mg kg-1

Table 4.1. Summary of characteristics of dogs with InvTCC enrolled in zeb dose escalation by dose cohort.
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0.7 mg kg-1
0
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1

2

1
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0

0
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0

0
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2
3

0

0

0

0

0

0

< 500 µL-1

4

0

0

1

0

0

1

100,000 µL-1 to
< lower limit
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1

0

1

0

1

0

0

50,000 to
99,000 µL-1

0

0

0

0

0

0

25,000 to
49,000 µL-1

Grade of Thrombocytopenia
2
3

n=1
a
The dogs enrolled in the 0.7 mg kg-1 cohort have not been enrolled long enough to evaluate toxicity at this time.

a

n=7

0.6 mg kg-1

n=4

0.5 mg kg-1

n=4

0.4 mg kg-1

n=9

0.3 mg kg-1

n=6

0.2 mg kg-1

1500 µL-1 to
< lower limit
of normal

1

Table 4.2. Selected hematologic toxicity by dose cohort in dogs with invasive transitional cell carcinoma treated with
zebularine.

0

0

0

0

0

0

< 25,000 µL-1

4

66

67

Figure 4.1. Progression free survival for 26 dogs treated with invasive
transitional cell carcinoma treated with zebularine. Median progression free
survival calculated using the Kaplan Meier product limit was 86 days (95% CI, 47.5124.5). Dogs were censored (open squares) if they were still alive and on zeb at the
time of analysis (n=7), if zeb was stopped for any reason other than disease
progression (n=4) or if dogs were lost to follow up (n=1).
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CHAPTER 5. CONCLUSION

5.1

Conclusion

Work published to date in rodents suggested that chronic zebularine (zeb)
administration was well tolerated. Limited information was available on the toxicity of
zeb in animals larger than rats and suggested that zeb may be hepatotoxic. This thesis
presented the findings of the first investigation of zeb in dogs. Initial pharmacokinetics
in laboratory dogs (n=3) and tumor bearing dogs (n=3) revealed that zeb undergoes
constant clearance in the dog. High dose daily zeb (4 mg kg-1) resulted in remarkable but
reversible neutropenia in laboratory dogs (n=3). High dose intermittent zeb (4 mg kg-1
once every 21 days) was well tolerated in tumor bearing dogs with no appreciable
toxicity. Based on the results of the initial pharmacokinetics and toxicity study, a phase I
dose escalation trial of zeb was initiated in dogs with InvTCC at a daily starting dose of
0.2 mg kg-1. Low dose zeb was well tolerated at daily doses of up to 0.5 mg kg-1, but
dose-limiting toxicity (DLT) in the form of neutropenia was detected at daily doses of 0.6
mg kg-1. Although evaluation of tumor response was not a primary goal of this study, the
disease control rate and median progression free survival was detected in dogs with
invasive transitional cell carcinoma (InvTCC).
High dose daily zeb resulted in unexpected and remarkable neutropenia in
laboratory dogs. While suspected hepatotoxicity had previously been reported in
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cynomolgus monkeys, remarkable neutropenia was not a feature of zeb toxicity
that had been described. The mechanism for neutropenia is unknown, but may reflect a
cytotoxic effect that can be seen when demethylating agents are used at high doses. The
toxicity mirrored that which is seen following treatment with traditional cytotoxic
chemotherapy as the most rapidly dividing granulocyte precursors appeared to be most
affected. Importantly, this toxicity was reversible with supportive care. The unexpected
myelosuppression at high zeb doses necessitated significant dose reductions before
enrolling dogs with InvTCC in a phase I trial of low dose daily zeb.
Low dose daily zeb was well tolerated up to doses of 0.5 mg kg-1. At 0.6
mg kg-1, DLT in the form of grade 3 neutropenia was detected. At the time of analysis,
only one dog had demonstrated a grade 3 neutropenia, so maximum tolerated dose (MTD)
was not reached as defined in the study. As more dogs in the higher dose cohorts are
evaluated, further toxicity may be identified. A total of 26 dogs with InvTCC were
treated with low dose daily zeb. Of these 26 dogs, 19 were evaluable for tumor response.
A disease control rate of 73.7% in a cohort of dogs that had been heavily pretreated is
impressive. Furthermore, one dog has experienced remarkable stable disease beyond 511
days at the time of data analysis. These results support that low dose oral zeb is a
promising therapy for the treatment of InvTCC in the dog. As the dog is a relevant model
of human InvTCC, this work supports further investigation of zeb’s potential in humans.
While a clear benefit following daily low dose zeb treatment was demonstrated in
dogs with InvTCC, future research should be directed at confirming that this benefit is a
result of DNA demethylation. Further work is needed to characterize DNA methylation
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in canine InvTCC. A variety of canine InvTCC cell lines are readily available and may
serve as an important tool to screen for gene specific methylation patterns that could then
be used to target the investigation of methylation patterns in tumor samples from dogs
and humans with InvTCC. Necropsy is a useful tool for banking large amounts of normal
tissue from dogs unaffected by cancer and dogs that have naturally occurring cancer for
use in this type of study. Exciting work has been performed in human clinical trials
combining demethylating agents with cytotoxic chemotherapy and this is a next logical
step that is currently undergoing pilot investigation at Purdue.
In conclusion, high dose daily zeb results in an unacceptable level of neutropenia
that was reversible. A less frequent high dose of zeb was well tolerated. As the optimal
dosing strategy for demethylating agents is likely frequent administration, a phase I dose
escalation trial of low dose oral zeb was performed. Daily low dose zeb at doses up to
0.5 mg kg-1 was well tolerated and resulted in promising disease control rates in dogs
with InvTCC. The work presented in this thesis supports further investigation of zeb in
dogs and humans with InvTCC.
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